arXiv subjects

Xiuli Xiao

Publications and source records attributed to Xiuli Xiao.

2 recordsLinked to original sources

arXiv2026

CorePath: A Breast-Specialized Pathology Foundation Model for Core Needle Biopsy Diagnosis and Risk-Controlled Report Generation

Breast core needle biopsy (CNB) is central to breast cancer diagnosis yet remains challenging because limited tissue sampling, lesion heterogeneity, and subtle morphologic overlap can obscure subtype distinctions. We developed CorePath, a breast-specialized multimodal pathology foundation model fine-tuned from PRISM using 7901 paired CNB whole-slide images and diagnostic reports from two centers. Evaluated across six CNB cohorts and two public breast pathology benchmarks without task-specific retraining, CorePath consistently outperformed PRISM across cancer detection, invasion assessment, and histological subtyping. It achieved weighted area under the receiver operating characteristic curves (AUCs) of 0.9526-0.9735 for five-class CNB histological subtyping across private centers. On public benchmarks, CorePath outperformed leading pathology foundation models, achieving the highest weighted AUCs of 0.7780 for BCNB invasive carcinoma subtyping, 0.8178 for BRACS lesion stratification, and 0.8252 for BRACS fine-grained classification. In report generation, CorePath reduced the overall non-breast hallucinations from 30.1% to 2.8%, demonstrating improved domain fidelity after breast-specific adaptation. CorePath-CRG further combined conformal subtype-confidence gating with Learn-Then-Test risk control to enable selective report release, subtype-level fallback, and deferral. CorePath-CRG achieved zero non-breast hallucinations among released outputs and showed the strongest overall performance in pathologist-validated LLM-based Evaluation Scores and quantitative report-generation metrics across most centers. These results demonstrate that domain-specialized foundation models with statistical risk control offer a promising approach for accurate breast CNB diagnosis and reliable report generation.

cs.CV↗

arXiv2023

Experts' cognition-driven ensemble deep learning for external validation of predicting pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer

In breast cancer, neoadjuvant chemotherapy (NAC) provides a standard treatment option for patients who have locally advanced cancer and some large operable tumors. A patient will have better prognosis when he has achieved a pathological complete response (pCR) with the treatment of NAC. There has been a trend to directly predict pCR to NAC from histological images based on deep learning (DL). However, the DL-based predictive models numerically have better performances in internal validation than in external validation. In this paper, we aim to alleviate this situation with an intrinsic approach. We propose an experts' cognition-driven ensemble deep learning (ECDEDL) approach. Taking the cognition of both pathology and artificial intelligence experts into consideration to improve the generalization of the predictive model to the external validation, ECDEDL can intrinsically approximate the working paradigm of a human being which will refer to his various working experiences to make decisions. ECDEDL was validated with 695 WSIs collected from the same center as the primary dataset to develop the predictive model and perform the internal validation, and was also validated with 340 WSIs collected from other three centers as the external dataset to perform the external validation. In external validation, ECDEDL improves the AUCs of pCR prediction from 61.52(59.80-63.26) to 67.75(66.74-68.80) and the Accuracies of pCR prediction from 56.09(49.39-62.79) to 71.01(69.44-72.58). ECDEDL was quite effective for external validation of predicting pCR to NAC from histological images in breast cancer, numerically approximating the internal validation.

physics.med-ph↗